News Releases

Date Title Teaser
11/09/18
Summary ToggleSurmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 9, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018 , and provided its
11/06/18
Summary Toggle12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018 Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.
11/01/18
Summary ToggleSurmodics Names Teri Sides as Chief Marketing Officer EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 1, 2018-- Surmodics, Inc.  (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer,
10/30/18
Summary ToggleSurmodics to Webcast Fourth Quarter Fiscal 2018 Earnings Conference Call on November 9 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 30, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter
08/07/18
Summary ToggleSurmodics to Present at 7th Annual Intellisight Investor Conference

Webcast is Live on Wednesday, August 15 , at 2:30 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 7, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will participate in the 7

08/06/18
Summary ToggleSurmodics Reports Third Quarter Fiscal 2018 Results

Raises Fiscal 2018 Revenue Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Aug. 6, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30,

07/31/18
Summary ToggleSurmodics IVD Launches Breakthrough MatrixGuard™ Diluent

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 31, 2018-- Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent.

07/26/18
Summary ToggleSurmodics to Webcast Third Quarter Fiscal 2018 Earnings Conference Call on August 6

Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 26, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal

05/30/18
Summary ToggleSurmodics to Present at Jefferies 2018 Global Healthcare Conference

Webcast is Live on Friday, June 8 , at 11:30 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 30, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and chief

05/16/18
Summary ToggleSurmodics Announces Leadership Change and Appointment of Interim CFO

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 16, 2018-- Surmodics , Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018 .

05/14/18
Summary ToggleSurmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics’ design, development, hydrophilic coating technology and manufacturing capabilities will advance innovative platform technology EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 14, 2018-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies

05/02/18
Summary ToggleSurmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 2, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 second quarter, ended March 31, 2018 , and raised financial outlook

05/02/18
Summary ToggleCORRECTING and REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 2, 2018-- The fifth bullet in the Recent Highlights section should read: EPS of $0.11 , Non-GAAP EPS of $0.07 (instead of EPS of $0.11 , Non-GAAP EPS of $0.15 ). The correct figure of $0.07 is represented in the Second Quarter Fiscal 2018 Financial Results

04/24/18
Summary ToggleSurmodics to Webcast Second Quarter Fiscal 2018 Earnings Conference Call on May 2

Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 24, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter

04/23/18
Summary ToggleSurmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter

Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 23, 2018-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it

03/15/18
Summary ToggleSurmodics to Present at Upcoming Investor Conferences EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 15, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and chief executive officer, and Andy LaFrence , vice president
02/27/18
Summary ToggleAbbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U.
AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT'S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS' PROPRIETARY DRUG-DELIVERY AND WHOLE-PRODUCT SOLUTIONS STRATEGY
02/13/18
Summary ToggleSurmodics to Host Virtual Annual Meeting of Shareholders Virtual Meeting on February 21 at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 13, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday,
02/08/18
Summary ToggleSurmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 8, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017 , and updated financial
01/30/18
Summary ToggleSurmodics to Webcast First Quarter Fiscal 2018 Earnings Conference Call on February 8 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 30, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal
01/22/18
Summary ToggleSurmodics Receives 510(K) Clearance for Telemark™ Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration Unique Coiled/Braided Shaft Technology Offers Superior Crossability Proprietary Hydrophilic Coating Provides Best-in-Class Lubricity and Low Particulates EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 22, 2018-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro